MIMEDX Announces Second Quarter 2026 Operating & Financial Results
MiMedx Group, Inc. reported second quarter 2026 net sales of $64 million, a 35% decrease year-over-year largely due to a 61% drop in Wound product sales affected by Medicare reimbursement changes. Surgical sales grew 15%, driven by key products AMNIOFIX® and AMNIOEFFECT®. The company is taking cost-reduction measures, targeting a return to profitab…